• Actinogen completed the final patient visit in its pivotal XanaMIA Alzheimer’s trial on Sept. 22.
• Topline results have not been presented yet; release remains scheduled for November 2026.
• Study tests oral Xanamem against placebo over 36 weeks, targeting brain cortisol control as a potential new treatment approach.
• Data readout is the next major catalyst, shaping regulatory planning and the program’s commercial outlook.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinogen Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230830PRIMZONEFULLFEED9832480) on September 23, 2026, and is solely responsible for the information contained therein.